English|中文
English|中文

​TongliBio announces TL-010 was granted with orphan drug designation by FDA

Time：2017-07-28

TongliBio announces TL-010 was granted with orphan drug designation by the US FDA for the treatment of Schistosomiasis.



Previous： TongliBio announcs to receive a clearance letter from the US FDA for its IND application of TL-010
Next： TongliBio announces to receive an early investment from two private investment groups including TF capital
Follow us:

Email：tl.office@tonglibio.com
Telephone：86-0512-58113269
Company Address：Rm 401, Bldg D, No.1 North Guotai Rd, Zhangjiagang, Suzhou, Jiangsu Province, PRC
苏ICP备13010604号

Verification code *
Submit
COPYRIGHT (©)  Tongli Biomedical Co. (TLB) Reserved 
Technical support: Three to Five Interconnection
TOP